Thermo Fisher inks deal to commercialized NGS diagnostics in Russia


Thermo Fisher Scientific (NYSE:TMO) has agreed to partner with diagnostic kitmaker First Genetics JCS on commercializing next-generation sequencing (NGS)-based diagnostics in Russia.

The deal enables First Genetics to market its F-Genetics NGS System and IVD assays to Russian labs for reproductive health testing and cancer diagnostics. The F-Genetics System is based on Thermo Fisher’s Ion GeneStudio S5 System.

Financial terms are not disclosed.





READ SOURCE

READ  Sensex gains 200 points, Nifty tops 10,100; Voda Idea falls 4%

LEAVE A REPLY

Please enter your comment!
Please enter your name here